Jonathan Stutters
Jonathan Stutters
Verified email at ucl.ac.uk
Title
Cited by
Cited by
Year
Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial
J Chataway, F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, ...
The Lancet Neurology 19 (3), 214-225, 2020
522020
Functional specialization and generalization for grouping of stimuli based on colour and motion
S Zeki, J Stutters
Neuroimage 73, 156-166, 2013
342013
A brain-derived metric for preferred kinetic stimuli
S Zeki, J Stutters
Open biology 2 (2), 120001, 2012
322012
Multiple sclerosis-secondary progressive multi-arm randomisation trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing …
P Connick, F De Angelis, RA Parker, D Plantone, A Doshi, N John, ...
BMJ open 8 (8), e021944, 2018
292018
Brain and cervical spinal cord atrophy in primary progressive multiple sclerosis: results from a placebo-controlled phase III trial (INFORMS)
Ö Yaldizli, D MacManus, J Stutters, DA Häring, F Lublin, MS Freedman, ...
MULTIPLE SCLEROSIS JOURNAL 21, 30-31, 2015
132015
MS-SMART Trial: a multi-arm phase 2b randomised, double blind, parallel group, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in …
MS-SMART Investigators
Multiple Sclerosis Journal 24, 986-987, 2018
52018
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT
F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, N John, ...
Efficacy and Mechanism Evaluation 7 (3), 1-72, 2020
42020
Safety and efficacy of bexarotene in patients with relapsing-remitting multiple sclerosis (CCMR One): a randomised, double-blind, placebo-controlled, parallel-group, phase 2a study
JWL Brown, NG Cunniffe, F Prados, B Kanber, JL Jones, E Needham, ...
The Lancet Neurology 20 (9), 709-720, 2021
32021
NAA is a marker of disability in secondary-progressive MS: A proton MR spectroscopic imaging study
BS Solanky, NA John, F DeAngelis, J Stutters, F Prados, T Schneider, ...
American Journal of Neuroradiology 41 (12), 2209-2218, 2020
32020
Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
HP Hartung, T Derfuss, BAC Cree, MP Sormani, K Selmaj, J Stutters, ...
Multiple Sclerosis Journal, 13524585211024997, 2021
22021
Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes
E Colato, J Stutters, C Tur, S Narayanan, DL Arnold, ...
Journal of Neurology, Neurosurgery & Psychiatry, 2021
12021
Phase 2 clinical trial evidence that a retinoid-X receptor agonist promotes remyelination in people with relapsing-remitting multiple sclerosis
J Brown, N Cunniffe, F Prados, B Kanber, J Jones, E Needham, ...
MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 43-44, 2020
12020
Spinal cord area is a stronger predictor of physical disability than brain volume in secondary progressive Multiple Sclerosis
F De Angelis, J Stutters, A Eshaghi, A Garcia, F Prados, D Plantone, ...
EUROPEAN JOURNAL OF NEUROLOGY 25, 23-23, 2018
12018
Colournamer, a synthetic observer for colour communication
D Mylonas, J Stutters, V Doval, L MacDonald
NewcastleGateshead Convention Bureau, 2013
12013
Efficacy and safety of temelimab in multiple sclerosis: Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study
HP Hartung, T Derfuss, BAC Cree, MP Sormani, K Selmaj, J Stutters, ...
Multiple Sclerosis Journal, 2021
2021
Predicting disability progression and cognitive worsening in multiple sclerosis using grey matter network measures
E Colato, J Stutters, C Tur, S Narayanan, DL Arnold, ...
medRxiv, 2021
2021
The effects of amiloride, fluoxetine and riluzole over 96 weeks on metabolic markers of brain injury in secondary progressive multiple sclerosis
N John, B Solanky, F De Angelis, J Stutters, F Prados, A Doshi, R Parker, ...
MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 428-428, 2020
2020
Baseline neuroaxonal integrity is associated with upper limb function at 96 weeks in secondary progressive multiple sclerosis
N John, B Solanky, F De Angelis, J Stutters, F Prados, A Doshi, R Parker, ...
MULTIPLE SCLEROSIS JOURNAL 26 (3_ SUPPL), 379-380, 2020
2020
Main results
F De Angelis, P Connick, RA Parker, D Plantone, A Doshi, N John, ...
Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary …, 2020
2020
Efficacy and Safety of Temelimab, an Antibody Antagonist of the Human Endogenous Retrovirus Type-W env Protein, in Participants with Relapsing Remitting Multiple Sclerosis: A …
HP Hartung, T Derfuss, B Cree, MP Sormani, K Selmaj, J Stutters, ...
2019
The system can't perform the operation now. Try again later.
Articles 1–20